论文部分内容阅读
目的探讨老年肺癌骨转移患者应用唑来膦酸联合化疗方案的临床效果,评价其安全性。方法选取2014年3月—2016年3月收治的48例老年肺癌骨转移患者,随机分为对照组(24例,应用常规化疗),观察组(24例,唑来膦酸联合化疗),对比两组治疗后的骨痛镇痛效果、碱性磷酸酶(AKP)水平、Ca2+浓度、骨不良事件发生率。结果观察组治疗后的AKP水平、Ca2+浓度均优于对照组,差异显著(P<0.05)。两组治疗后骨痛缓解1级、2级、3级人数比较,差异无显著性(P>0.05);观察组治疗后骨痛缓解0级人数高于对照组(P<0.05),差异显著(P<0.05)。观察组治疗后骨不良事件发生率低于对照组。结论对老年肺癌骨转移患者应用唑来膦酸联合化学治疗方案的疗效确切,安全可靠,促进患者康复,值得临床推广。
Objective To investigate the clinical effect of zoledronic acid combined with chemotherapy in elderly patients with bone metastasis of lung cancer and evaluate its safety. Methods Forty-eight elderly patients with lung cancer with bone metastasis from March 2014 to March 2016 were randomly divided into control group (n = 24) treated with conventional chemotherapy and observation group (n = 24) treated with zoledronic acid combined with chemotherapy The analgesic effect of bone pain, AKP level, Ca2 + concentration and the incidence of bone adverse events in both groups after treatment. Results The AKP level and Ca2 + concentration in the observation group were better than those in the control group (P <0.05). There was no significant difference in grade 1, grade 2 and grade 3 after treatment between two groups (P> 0.05). The number of grade 0 patients in observation group after treatment was significantly higher than that in control group (P <0.05) (P <0.05). The incidence of bone-adverse events in observation group was lower than that in control group. Conclusion The application of zoledronic acid combined with chemotherapy in elderly patients with bone metastasis of lung cancer is effective, safe and reliable, which can promote the rehabilitation of patients and is worthy of clinical promotion.